The effects of the MA-PI 2 macrobiotic diet in the treatment of type 2 diabetes and diet-induced metabolic acidosis

2014 ◽  
Vol 30 (8) ◽  
pp. 659-660
Author(s):  
Francesco Fallucca ◽  
Sara Fallucca ◽  
Mario Pianesi
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Acidosis ◽  
Macrobiotic Diet

scholarly journals Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report

2019 ◽  
Author(s):  
Anh Dat Nguyen ◽  
Chinh Quoc Luong ◽  
Hieu Chu Chi ◽  
Van Khoa Dieu Nguyen ◽  
Chi Van Nguyen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Acidosis ◽  
Allergic Reaction ◽  
Diabetic Ketoacidosis ◽  
Human Insulin ◽  
Insulin Infusion ◽  
Recombinant Human Insulin ◽  
Insulin Allergy ◽  
Allergic Symptoms

Abstract BackgroundDiabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Allergic reaction to insulin is rare, especially when using recombinant human insulin. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction such as anaphylaxis. A limited number of cases have been reported on the treatment of severe DKA in patients with type 2 diabetes with insulin allergy. Here, we describe a patient with type 2 diabetes with insulin allergy in which severe DKA resolved after the initiation of continuous intravenous (IV) recombinant human insulin infusion.Case presentationA 58-year-old man with type 2 diabetes initiated subcutaneous insulin administration (SIA) after failure of oral antidiabetic treatment. Symptoms of an allergic reaction developed, including pruritic wheals appearing within 10 minutes of injection and lasting over 24 hours. Both skin prick and intradermal tests were positive with different types of insulin. Two days before admission, he stopped SIA because of allergic symptoms and then experienced weakness and upper abdominal pain. On admission, he was in severe metabolic acidosis with a pH of 6.984 and bicarbonate of 2.5 mmol/litre. The blood glucose level was 20.79 mmol/litre, BUN 4.01 mmol/litre, creatinine 128 µmol/litre, and urinary ketone 11.44 mmol/litre. Over 24 hours, metabolic acidosis was refractory to IV fluids, bicarbonate and potassium replacement, as well as haemodialysis. Ultimately, he received continuous IV recombinant human insulin infusion at a rate of 0.1 units/kg/hour, in combination with haemodiafiltration, and no further allergic reactions were observed. On day 5, ketonaemia and metabolic acidosis completely resolved. He had transitioned from IV insulin infusion to SIA on day 14. He was discharged on day 21 with SIA treatment. Three months later, he had good glycaemic control but still had allergic symptoms at the insulin injection sites.ConclusionsIn this patient, SIA caused an allergic reaction, in contrast to continuous IV insulin infusion for which allergic symptoms did not appear. Continuous IV recombinant human insulin infusion in combination with haemodiafiltration could be an option for the treatment of severe DKA in patients with diabetes with insulin allergy.

scholarly journals Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Anh Dat Nguyen ◽  
Chinh Quoc Luong ◽  
Hieu Chi Chu ◽  
Van Khoa Dieu Nguyen ◽  
Chi Van Nguyen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Acidosis ◽  
Allergic Reaction ◽  
Diabetic Ketoacidosis ◽  
Human Insulin ◽  
Insulin Infusion ◽  
Recombinant Human Insulin ◽  
Insulin Allergy ◽  
Allergic Symptoms

Abstract Background Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Allergic reaction to insulin is rare, especially when using recombinant human insulin. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction such as anaphylaxis. A limited number of cases have been reported on the treatment of severe DKA in patients with type 2 diabetes with insulin allergy. Here, we describe a patient with type 2 diabetes with insulin allergy in which severe DKA resolved after the initiation of continuous intravenous (IV) recombinant human insulin infusion. Case presentation A 58-year-old man with type 2 diabetes initiated subcutaneous insulin administration (SIA) after failure of oral antidiabetic treatment. Symptoms of an allergic reaction developed, including pruritic wheals appearing within 10 min of injection and lasting over 24 h. Both skin prick and intradermal tests were positive with different types of insulin. Two days before admission, he stopped SIA because of allergic symptoms and then experienced weakness and upper abdominal pain. On admission, he was in severe metabolic acidosis with a pH of 6.984 and bicarbonate of 2.5 mmol/litre. The blood glucose level was 20.79 mmol/litre, BUN 4.01 mmol/litre, creatinine 128 μmol/litre, and urinary ketone 11.44 mmol/litre. Over 24 h, metabolic acidosis was refractory to IV fluids, bicarbonate and potassium replacement, as well as haemodialysis. Ultimately, he received continuous IV recombinant human insulin infusion at a rate of 0.1 units/kg/hour, in combination with haemodiafiltration, and no further allergic reactions were observed. On day 5, ketonaemia and metabolic acidosis completely resolved. He had transitioned from IV insulin infusion to SIA on day 14. He was discharged on day 21 with SIA treatment. Three months later, he had good glycaemic control but still had allergic symptoms at the insulin injection sites. Conclusions In this patient, SIA caused an allergic reaction, in contrast to continuous IV insulin infusion for which allergic symptoms did not appear. Continuous IV recombinant human insulin infusion in combination with haemodiafiltration could be an option for the treatment of severe DKA in patients with diabetes with insulin allergy.

scholarly journals Ma-Pi 2 macrobiotic diet intervention during 21 days in adults with type 2 diabetes mellitus, Ghana 2011

2014 ◽  
Vol 2 (1) ◽  
pp. 3 ◽  
Author(s):  
Braimah Baba Abubakari ◽  
Mohammed M Ibrahim ◽  
Iddrisu Mutawakilu ◽  
Carmen Porrata-Maury ◽  
Vladimir Ruíz- Alvarez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diet Intervention ◽  
Macrobiotic Diet

Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes

2019 ◽  
Vol 76 (23) ◽  
pp. 1930-1933 ◽  
Author(s):  
Naseer Khan ◽  
Katie Tso ◽  
Joan Broussard ◽  
Monica Dziuba
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Adverse Effect ◽  
Type 1 Diabetes ◽  
Metabolic Acidosis ◽  
Fanconi Syndrome ◽  
Subcutaneous Insulin ◽  
Laboratory Test Results

Abstract Purpose Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which received U.S. Food and Drug Administration approval in 2013 for the treatment of type 2 diabetes mellitus. Fanconi syndrome is a rare acquired disorder which typically occurs in adults as an adverse effect of medications. The literature includes few case reports of Fanconi syndrome caused by the use of canagliflozin. Here, we present a case of Fanconi syndrome in a patient with type 1 diabetes previously miscategorized as type 2 diabetes. Summary A 32-year-old woman with a 6-year history of type 2 diabetes was started on canagliflozin. Within 2 months of therapy initiation, she began to develop symptoms of high anion gap metabolic acidosis. Further laboratory test results showed severe life-threatening hypophosphatemia. Further investigation by nephrology revealed the presence of Fanconi syndrome. During the admission, she was found to have clinical and laboratory features of type 1 (insulin-dependent) diabetes. After discontinuation of canagliflozin, she was treated with intravenous (i.v.) fluids for hydration, subcutaneous insulin, and i.v. potassium phosphate. She recovered from all metabolic acidosis and electrolyte abnormalities. Conclusion Fanconi syndrome is a rare, exogenously acquired disorder in adults that often develops as an adverse effect of medication therapy. Our patient presented with Fanconi syndrome as a complication of canagliflozin use for the treatment of presumed type 2 diabetes. She was then started on subcutaneous insulin monotherapy for the treatment of type 1 diabetes mellitus.

scholarly journals Ma‐Pi 2 macrobiotic diet and type 2 diabetes mellitus: pooled analysis of short‐term intervention studies

2014 ◽  
Vol 30 (S1) ◽  
pp. 55-66 ◽  
Author(s):  
C. Porrata‐Maury ◽  
M. Hernández‐Triana ◽  
V. Ruiz‐Álvarez ◽  
M. E. Díaz‐Sánchez ◽  
F. Fallucca ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Intervention Studies ◽  
Pooled Analysis ◽  
Short Term ◽  
Macrobiotic Diet
Sign in / Sign up

Export Citation Format

Share Document